Harvard Bioscience, Inc. (HBIO)

Harvard Bioscience Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	6.5	8.61	4.11	4.28	4.51	7.82
Cash & Short-Term Investments	6.5	8.61	4.11	4.28	4.51	7.82
Cash Growth	-12.62%	109.69%	-4.09%	-4.99%	-42.36%	-5.96%
Accounts Receivable	14.5	16.04	14.87	16.1	16.71	21.83
Receivables	14.5	16.04	14.87	16.1	16.71	21.83
Inventory	22.23	20.81	23.25	24.72	26.44	27.59
Other Current Assets	3.23	2.76	2.9	3.94	3.47	4.34
Total Current Assets	46.46	48.23	45.12	49.04	51.12	61.58
Property, Plant & Equipment	11.75	11.96	11.24	8.75	9.18	10.31
Long-Term Investments	-	-	-	3.5	-	-
Goodwill	9.33	9.56	56.32	57.07	56.26	57.69
Other Intangible Assets	6.22	7.64	11.13	16.04	21.01	27.39
Long-Term Deferred Tax Assets	-	-	0.09	0.44	0.33	0.21
Other Long-Term Assets	2.53	2.69	2.74	2.54	7.45	5.17
Total Assets	76.29	80.07	126.64	137.37	145.36	162.34

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	6.22	3.65	4.79	5.55	6.45	4.91
Accrued Expenses	2.76	3.56	2.26	4.43	3.87	6.53
Current Portion of Long-Term Debt	-	-	36.96	5.86	3.81	3.24
Current Portion of Leases	1.6	1.53	1.16	1.42	2.14	2.14
Current Income Taxes Payable	-	-	-	-	-	0.22
Current Unearned Revenue	3.6	3.45	3.81	4.51	3.37	4.27
Other Current Liabilities	10.61	9.78	5.99	4.78	3.62	4.01
Total Current Liabilities	24.79	21.96	54.96	26.54	23.25	25.32
Long-Term Debt	36.68	35.87	0.1	30.9	43.01	45.1
Long-Term Leases	5.93	6.88	6.38	4.79	5.28	6.49
Long-Term Deferred Tax Liabilities	0.31	0.32	0.71	0.78	0.59	1.56
Other Long-Term Liabilities	1.16	1.31	1.16	1.28	1.01	0.49
Total Liabilities	68.87	66.34	63.3	64.29	73.14	78.94

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.45	0.45	0.44	0.43	0.45	0.45
Additional Paid-In Capital	240.39	239.67	236.58	232.44	229.01	225.65
Retained Earnings	-221.04	-214.71	-158.01	-145.61	-142.19	-132.67
Comprehensive Income & Other	-12.38	-11.67	-15.67	-14.19	-15.05	-10.03
Shareholders' Equity	7.42	13.73	63.34	73.07	72.22	83.4
Total Liabilities & Equity	76.29	80.07	126.64	137.37	145.36	162.34

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	44.21	44.28	44.59	42.97	54.24	56.96
Net Cash (Debt)	-37.7	-35.66	-40.49	-35.19	-49.73	-49.14
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-8.43	-8.03	-9.30	-8.30	-12.01	-12.18
Filing Date Shares Outstanding	4.55	4.47	4.41	4.34	4.22	4.12
Total Common Shares Outstanding	4.55	4.47	4.41	4.34	4.21	4.11
Working Capital	21.67	26.27	-9.84	22.5	27.88	36.27
Book Value Per Share	1.63	3.07	14.37	16.84	17.16	20.27
Tangible Book Value	-8.13	-3.46	-4.12	-0.03	-5.05	-1.67
Tangible Book Value Per Share	-1.79	-0.77	-0.93	-0.01	-1.20	-0.41
Machinery	-	20.24	18.36	15.95	15.71	15.3
Leasehold Improvements	-	2.67	2.57	2.42	2.51	2.56

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 11, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 7, 2026

Data Sources Report a data error